CDE Catalog

***Please contact the NINDS CDE Team (NINDSCDE@emmes.com) if you encounter any search difficulties.***

The CDE Catalog is a directory of the available NINDS CDEs. Users can search the Catalog to isolate a subset of the CDEs (e.g., all stroke-specific CDEs, etc.), and to view and download details about the CDEs.

Select any filter below to search the CDE Catalog.

For best results, clear form between searches. In addition, when specifying NeuroRehab, Sport-Related Concussion (SRC) or Traumatic Brain Injury (TBI) as the Disease, please select a Subdisease as well.

NeuroRehab Comprehensive includes all NeuroRehab CDE recommendations. NeuroRehab General includes all NeuroRehab CDE recommendations that are not disease specific. All other NeuroRehab Subdiseases include recommendations specific to existing NINDS CDE project disorders.

Choose your Time Frame for your SRC study (Acute (time of injury until 72 hours), Subacute (after 72 hours to 3 months), and Persistent/Chronic (3 months and greater post-concussion) or Comprehensive if your study falls across the study time frames.

Choose your type of TBI study (Acute Hospitalized, Concussion/Mild TBI, Moderate/Severe TBI: Rehabilitation, or Epidemiology) or Comprehensive if your study falls outside of the study types or incorporates aspects of more than one type of study.

Search Form

Displaying 351 - 375 of 409
Operations
Selected 25 rows in this page.  
The search results below can be downloaded by clicking the checkboxes on the far left side of the table. Select the header checkbox to select all CDEs listed on the first page. Then choose CDE Detailed Report from the Choose an operation dropdown menu.
CDE ID CDE Name Definition Classification CRF Name Copyrighted or trademarked Disease Name Subdisease Name
C17756 Striatum atrophy claustrum atrophy severity result

Quantitative result of the severity of atrophy located in the claustrum

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C14960 Diagnosis based abnormality type

What kind of abnormalities was the diagnosis based on?

Supplemental Medical History of Huntington's Disease Huntington's Disease Huntington's Disease
C15078 Brain atrophy cerebellum cortical neuronal loss in effective layer severity result

Quantitative result of the severity of cortical neuronal loss in the effective layer of the cerebellum

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C08232 Drug or substance illicit use ever indicator

Indicator of participant's/subject's use of illegal drugs, prescription or over-the-counter drugs at any point in his/her lifetime for purposes other than those for which they are meant to be used, or in large amounts

Supplemental Non-prescribed Drug Use Questionnaire Huntington's Disease Huntington's Disease
C17681 Family history collection source

The source of collected family history data

Supplemental Family History Huntington's Disease Huntington's Disease
C10576 Imaging in plane resolution axis 1 measurement

Measurement of axis 1 of in-plane spatial resolution used in imaging acquisition

Supplemental Magnetic Resonance (MR) Localization Imaging Huntington's Disease Huntington's Disease
C17764 Striatum atrophy red nucleus atrophy severity result

Quantitative result of the severity of atrophy located in the red nucleus

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C17740 Chorea anatomic site physician developing type

Anatomic site of the participant's/subject's body affected by chorea as noted by a physician as a developing issues from disease

Supplemental Medical History of Huntington's Disease Huntington's Disease Huntington's Disease
C15086 Ischemic or hemorrhagic changes event category

Category of the ischemic or hemorrhagic changes

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C17687 Non-prescribed controlled psychoactive drug substance sedative barbiturate text

The text specifying the drugs within the 'Sedatives-barbiturates and others: phenobarbital, Seconol, Nembutal, Dorieden, Quaalude, Amytal, Fiorinal, downers,' category as unprescribed, controlled psychoactive drugs or substances used by the participant/subject

Supplemental Non-prescribed Drug Use Questionnaire Huntington's Disease Huntington's Disease
C08079 Full biological brothers count

Count of full biological brothers the participant/subject has

Supplemental History of Early Exposure to Huntington's Disease Huntington's Disease Huntington's Disease
C14965 Imaging artifacts indicator

Indicator of any obvious artifacts in the image

Supplemental Magnetic Resonance (MR) Localization Imaging Huntington's Disease Huntington's Disease
C19060 Physician specialty other text

The free-text field related to 'Physician specialty type' specifying other text. The specialty of the physician who made the diagnosis

Supplemental Medical History of Huntington's Disease Huntington's Disease Huntington's Disease
C15094 Lacunes single or multiple description text

The text description of the lacunes

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C15054 Brain atrophy substantia nirgra pars compacta neuronal loss severity result

Quantitative result of the severity of neuronal loss in the pars compacta

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C14951 Motor symptom first appeared self report date and time

Date of the first motor symptom(s) as noted by the participant/subject

Supplemental Medical History of Huntington's Disease Huntington's Disease Huntington's Disease
C08087 Sibling death age value

Age of sibling when he/she died

Supplemental History of Early Exposure to Huntington's Disease Huntington's Disease Huntington's Disease
C18708 Imaging pulse sequence type other text

The free-text field related to 'Imaging pulse sequence type', specifying other text. Type of imaging pulse sequence used

Supplemental Magnetic Resonance (MR) Localization Imaging Huntington's Disease Huntington's Disease
C15102 Arteriosclerosis indicator

Indicator of arteriosclerosis (small parenchymal arteriolar disease)

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C15062 Brain atrophy nucleus coeruleus Lewy body containing neurons and Lewy neurites severity result

Quantitative result of the severity of lewy-body containing neurons (LBCN) and lewy neurites (LN) in the nucleus coeruleus

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C08110 Preschool end date

Date participant/subject ended preschool

Supplemental History of Early Exposure to Huntington's Disease Huntington's Disease Huntington's Disease
C11138 Country of origin paternal ISO code

The ISO 3166-1 alpha-2 code for the participant's father's country of origin

Supplemental Demographics Huntington's Disease Huntington's Disease
C02411 Laterality type

Laterality type relative to the anatomic site of the body examined or affected

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C15110 Atherosclerotic luminal stenosis percentage range

Range for the estimated luminal stenosis percentage if stenotic vascular changes (of the circle of Willis)

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
C15070 Brain atrophy medulla oblongata dorsal nucleus of vagus reticular formation severity result

Quantitative result of the severity of dorsal nucleus of vagus reticular formation: LBCN and LN in the medulla oblongata

Supplemental Neuropathology Data Form Huntington's Disease Huntington's Disease
Displaying 351 - 375 of 409

The NINDS CDE Team does not post proprietary instruments/scales recommended by the CDE Working Groups on this website. This includes, but is not limited to, copyrighted or trademarked instruments/scales. Information about recommended instruments can be found in the Notice of Copyright (NOC) documents under ‘CRF Module/Guideline’ on each disorder’s data standards page. For any questions regarding these instruments/scales please contact the corresponding owner/author. The NINDS CDE Team is not responsible for the availability or content of these external sites, nor does the NINDS CDE Team endorse, warrant or guarantee the products, services or information described or offered at these other internet sites.